Literature DB >> 2343041

Epidermal growth factor and its receptors in human pancreatic carcinoma.

Y F Chen1, G Z Pan, X Hou, T H Liu, J Chen, C Yanaihara, N Yanaihara.   

Abstract

The role of epidermal growth factor (EGF) in oncogenesis and progression of malignant tumors is a subject of vast interest. In this study, radioimmunoassay and radioreceptor assay of EGF were established. EGF contents in malignant and benign pancreatic tumors, in normal pancreas tissue, and in culture media of a human pancreatic carcinoma cell line were determined. EGF receptor binding studies were performed. It was shown that EGF contents in pancreatic carcinomas were significantly higher than those in normal pancreas or benign pancreatic tumors. EGF was also detected in the culture medium of a pancreatic carcinoma cell line. The binding of 125I-EGF to the pancreatic carcinoma cells was time and temperature dependent, reversible, competitive, and specific. Scatchard analysis showed that the dissociation constant of EGF receptor was 2.1 X 10(-9) M, number of binding sites was 1.3 X 10(5) cell. These results indicate that there is an over-expression of EGF/EGF receptors in pancreatic carcinomas, and that an autocrine regulatory mechanism may exist in the growth-promoting effect of EGF on tumor cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2343041     DOI: 10.1097/00006676-199005000-00006

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  10 in total

Review 1.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

2.  Transforming growth factor alpha (TGF-alpha) increases cell number in a human pancreatic cancer cell line but not in normal mouse pancreas.

Authors:  B Kullenberg; C Jansen; N Fredäng; B Ohlsson; J Axelson
Journal:  Int J Pancreatol       Date:  2000-12

3.  Characterisation of oestrogen receptor, progesterone receptor, trefoil factor 1, and epidermal growth factor and its receptor in pancreatic cystic neoplasms and pancreatic ductal adenocarcinoma.

Authors:  T-S Yeh; Y-Y Jan; C-T Chiu; Y-B Ho; T-C Chen; K-F Lee; K-M Chan; J-C Hsu; T-L Hwang; M-F Chen
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

4.  Measurement of pS2 protein in pancreatic cyst fluids. Evidence for a potential role of pS2 protein in the pathogenesis of mucinous cystic tumors.

Authors:  J M Yang; J Lee; J F Southern; A L Warshaw; E Dhanak; K B Lewandrowski
Journal:  Int J Pancreatol       Date:  1998-12

5.  The inhibitory effect of an EGF receptor-specific tyrosine kinase inhibitor on pancreatic cancer cell lines was more potent than inhibitory antibodies against the receptors for EGF and IGF I.

Authors:  M Kobari; B Kullenberg; A Björkman; S Matsuno; I Ihse; J Axelson
Journal:  Int J Pancreatol       Date:  1998-10

6.  A mucous histochemical and immunohistochemical study of precancerous and neoplastic lesions in the human pancreas.

Authors:  K Yamao; S Nakazawa; M Fujimoto; H Tsuda; K Matsumoto; T Iwase
Journal:  Int J Pancreatol       Date:  1993-08

7.  Epidermal growth factor mediates detachment from and invasion through collagen I and Matrigel in Capan-1 pancreatic cancer cells.

Authors:  Andrew J Shirk; Rahul Kuver
Journal:  BMC Gastroenterol       Date:  2005-03-31       Impact factor: 3.067

8.  Human pancreatic cancer cell lines do not express receptors for somatostatin.

Authors:  J Gillespie; G J Poston; M Schachter; P J Guillou
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

9.  Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins.

Authors:  M Löhr; B Trautmann; M Göttler; S Peters; I Zauner; B Maillet; G Klöppel
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

10.  Inhibition of pancreatic cancer cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors.

Authors:  J Gillespie; J F Dye; M Schachter; P J Guillou
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.